Publications by authors named "Marlene Modi"

Claim this Profile
L
Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit.
Jeffrey W-D Foy, Kay Rittenhouse, Marlene Modi, Manju Patel

J Ocul Pharmacol Ther· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.

Ophthalmology· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerated drug development through combined phase 2/3 clinical trial design.
Emmett T Cunningham, Loni da Silva, Evelyn M Harrison, Marlene W Modi, Denis O'Shaughnessy

Arch Ophthalmol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon alfa-2a (40KD): a potent long-acting form of interferon alfa-2a for the treatment of hepatitis C.
Marlene W Modi, Matthew W Lamb, Mari Shiomi

Adv Exp Med Biol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
Eva Herrmann, Jung-Hun Lee, George Marinos, Marlene Modi, Stefan Zeuzem

Hepatology· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.
K Rajender Reddy, Marlene W Modi, Simon Pedder

Adv Drug Deliv Rev· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis